These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21821523)

  • 81. No-reflow: a heterogeneous clinical phenomenon with multiple therapeutic strategies.
    Galiuto L; Crea F
    Curr Pharm Des; 2006; 12(29):3807-15. PubMed ID: 17073679
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion.
    Golino P; Maroko PR; Carew TE
    Circulation; 1987 Jan; 75(1):292-8. PubMed ID: 3791611
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Coronary No-Reflow Phenomenon in Clinical Practice.
    Scarpone M; Cenko E; Manfrini O
    Curr Pharm Des; 2018; 24(25):2927-2933. PubMed ID: 29962336
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Imaging the myocardial microcirculation post-myocardial infarction.
    White SK; Hausenloy DJ; Moon JC
    Curr Heart Fail Rep; 2012 Dec; 9(4):282-92. PubMed ID: 22926994
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Meta-analysis of MACE in MI: what's the MO?
    Reichek N
    JACC Cardiovasc Imaging; 2014 Sep; 7(9):953-5. PubMed ID: 25212801
    [No Abstract]   [Full Text] [Related]  

  • 86. Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine.
    Forman MB; Jackson EK
    Clin Cardiol; 2007 Nov; 30(11):583-5. PubMed ID: 18000974
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Effect of adenosine on the size of experimental myocardial infarction and "no re-flow" areas].
    Eliseev VV; Krylova IB; Evdokimova NR
    Kardiologiia; 1988 Dec; 28(12):98-9. PubMed ID: 3244268
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Novel insights into an "old" phenomenon: the no reflow.
    Durante A; Camici PG
    Int J Cardiol; 2015; 187():273-80. PubMed ID: 25838230
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cardiac MR assessment of microvascular obstruction.
    Abbas A; Matthews GH; Brown IW; Shambrook JS; Peebles CR; Harden SP
    Br J Radiol; 2015 Mar; 88(1047):20140470. PubMed ID: 25471092
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A role for pericytes in coronary no-reflow.
    O'Farrell FM; Attwell D
    Nat Rev Cardiol; 2014 Jul; 11(7):427-32. PubMed ID: 24776704
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions.
    Valero SJ; Moreno R; Reyes RM; Recalde AS; Galeote G; Calvo L; Villate A; Sendón JL
    Cardiovasc Hematol Agents Med Chem; 2008 Apr; 6(2):125-9. PubMed ID: 18473777
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Etiology and clinical implications of microvascular dysfunction in patients with acute myocardial infarction.
    Ito H
    Int Heart J; 2014; 55(3):185-9. PubMed ID: 24806384
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prevention and treatment of no-reflow phenomenon by targeting the coronary microcirculation.
    Feher A; Chen SY; Bagi Z; Arora V
    Rev Cardiovasc Med; 2014; 15(1):38-51. PubMed ID: 24762465
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Luteolin alleviates ischemia/reperfusion injury-induced no-reflow by regulating Wnt/β-catenin signaling in rats.
    Qin X; Qin H; Li Z; Xue S; Huang B; Liu X; Wang D
    Microvasc Res; 2022 Jan; 139():104266. PubMed ID: 34688627
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.
    Kunadian V; Zorkun C; Williams SP; Biller LH; Palmer AM; Ogando KJ; Lew ME; Nethala N; Gibson WJ; Marble SJ; Buros JL; Gibson CM
    J Thromb Thrombolysis; 2008 Dec; 26(3):234-42. PubMed ID: 18818881
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Modulation of individual susceptibility to the no-reflow phenomenon after acute myocardial infarction.
    Iwakura K
    Curr Pharm Des; 2013; 19(25):4519-28. PubMed ID: 23270556
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Intramyocardial haemorrhage after acute myocardial infarction.
    Betgem RP; de Waard GA; Nijveldt R; Beek AM; Escaned J; van Royen N
    Nat Rev Cardiol; 2015 Mar; 12(3):156-67. PubMed ID: 25403783
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cine MRI assessment of extensive late no reflow in severe ischemic cardiomyopathy.
    Leurent G; Langella B; Boulmier D
    Arch Cardiovasc Dis; 2008 Sep; 101(9):589-91. PubMed ID: 19041844
    [No Abstract]   [Full Text] [Related]  

  • 99. [No reflow phenomenon in acute myocardial infarction].
    Ito H
    Nihon Rinsho; 2011 Sep; 69 Suppl 7():142-6. PubMed ID: 22518981
    [No Abstract]   [Full Text] [Related]  

  • 100. The challenge of microvascular obstruction after primary percutaneous coronary intervention.
    Niccoli G
    Curr Vasc Pharmacol; 2013 Mar; 11(2):243-4. PubMed ID: 23506501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.